Crewe Advisors’s Quest Diagnostics DGX Stock Holding History

Crewe Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06K	Buy	+5	New	+$981	﹤0.01%	1046
2025 Q3	–	Sell	-2	Closed	-$360	–	982
2025 Q2	$360	Hold	2	–	–	﹤0.01%	677
2025 Q1	$339	Hold	2	–	–	﹤0.01%	662
2024 Q4	$302	Sell	2 -28	-93%	-$4.36K	﹤0.01%	611
2024 Q3	$4.66K	Hold	30	–	–	﹤0.01%	589
2024 Q2	$4.11K	Hold	30	–	–	﹤0.01%	834
2024 Q1	$3.99K	Buy	+30	New	+$3.89K	﹤0.01%	773
2023 Q2	–	Sell	-22	Closed	-$3.11K	–	907
2023 Q1	$3.11K	Hold	22	–	–	﹤0.01%	684
2022 Q4	$3.44K	Sell	22 -48	-69%	-$6.9K	﹤0.01%	748
2022 Q3	$9K	Buy	70 +16	+30%	+$2.11K	﹤0.01%	688
2022 Q2	$7K	Buy	+54	New	+$7.36K	﹤0.01%	681
2020 Q4	–	Sell	-9	Closed	-$1K	–	504
2020 Q3	$1K	Buy	+9	New	+$1.06K	﹤0.01%	572
2020 Q1	–	Sell	-93	Closed	-$10K	–	194
2019 Q4	$10K	Buy	+93	New	+$9.7K	﹤0.01%	181

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Crewe Advisors's DGX Position: Q2 2026 in Review

Crewe Advisors opened a new position in Quest Diagnostics (DGX) in Q2 2026: 5 shares worth $1.06K. The stake represents ﹤0.01% of the portfolio and ranks #1046 among its holdings. This is a return to the name: Crewe Advisors previously reported a position in DGX as recently as Q2 2025.

Crewe Advisors first reported a position in DGX in Q4 2019 and has held it in 13 quarters since. The position peaked at $10K in Q4 2019. 1,110 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Crewe Advisors held 5 shares of Quest Diagnostics worth $1.06K as of Q2 2026.
Quest Diagnostics was a new Crewe Advisors position in Q2 2026.
Quest Diagnostics made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #1046 holding.
Crewe Advisors first reported a position in Quest Diagnostics in Q4 2019 and has held it in 13 quarters since.
Crewe Advisors's Quest Diagnostics position peaked at $10K in Q4 2019.
1,110 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.